1. Home
  2. MDWD vs WALD Comparison

MDWD vs WALD Comparison

Compare MDWD & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • WALD
  • Stock Information
  • Founded
  • MDWD 2000
  • WALD 1988
  • Country
  • MDWD Israel
  • WALD United States
  • Employees
  • MDWD N/A
  • WALD N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • WALD Package Goods/Cosmetics
  • Sector
  • MDWD Health Care
  • WALD Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • WALD Nasdaq
  • Market Cap
  • MDWD 195.2M
  • WALD 228.8M
  • IPO Year
  • MDWD 2014
  • WALD 2021
  • Fundamental
  • Price
  • MDWD $17.66
  • WALD $1.82
  • Analyst Decision
  • MDWD Strong Buy
  • WALD Strong Buy
  • Analyst Count
  • MDWD 2
  • WALD 5
  • Target Price
  • MDWD $35.00
  • WALD $4.96
  • AVG Volume (30 Days)
  • MDWD 60.7K
  • WALD 45.9K
  • Earning Date
  • MDWD 11-20-2025
  • WALD 11-11-2025
  • Dividend Yield
  • MDWD N/A
  • WALD N/A
  • EPS Growth
  • MDWD N/A
  • WALD N/A
  • EPS
  • MDWD N/A
  • WALD N/A
  • Revenue
  • MDWD $19,858,000.00
  • WALD $273,868,000.00
  • Revenue This Year
  • MDWD $21.39
  • WALD $10.37
  • Revenue Next Year
  • MDWD $23.01
  • WALD $14.37
  • P/E Ratio
  • MDWD N/A
  • WALD N/A
  • Revenue Growth
  • MDWD N/A
  • WALD 25.55
  • 52 Week Low
  • MDWD $14.14
  • WALD $1.48
  • 52 Week High
  • MDWD $22.51
  • WALD $4.18
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 42.31
  • WALD 48.21
  • Support Level
  • MDWD $17.50
  • WALD $1.64
  • Resistance Level
  • MDWD $18.58
  • WALD $1.96
  • Average True Range (ATR)
  • MDWD 0.60
  • WALD 0.13
  • MACD
  • MDWD -0.13
  • WALD -0.00
  • Stochastic Oscillator
  • MDWD 2.88
  • WALD 47.50

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

Share on Social Networks: